04:03 PM EST, 11/19/2025 (MT Newswires) -- Salarius Pharmaceuticals ( SLRX ) said Wednesday that S&P Global's ( SPGI ) Capital IQ platform incorrectly indicated the company had been delisted following its merger with Decoy Therapeutics.

The company said its shares continue to trade normally on Nasdaq under the SLRX ticker, and it is working to correct the misinformation.

Salarius closed an $8 million public offering and completed its merger with Decoy on Nov. 13. As of date, the combined company has roughly $14 million in pro forma cash and about 5.9 million shares outstanding.

Price: 0.78, Change: -0.08, Percent Change: -9.45